Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003129 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
A Phase 2 study of Bladder Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 10
- Study locations
NCT00003129: Completed Phase 2 study of Bladder Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00003129 is a Phase 2 study of Bladder Cancer that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 75 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003129, a Phase 2 study of Bladder Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating patients with early-stage bladder cancer that has not responded to BCG therapy.
Conditions Studied
Interventions
- DRUG valrubicin
Study Locations (10)
Wisconsin
- CCOP - Green Bay - Green Bay
- Veterans Affairs Medical Center - Madison - Madison
- University of Wisconsin Comprehensive Cancer Center - Madison
- Medical College of Wisconsin - Milwaukee
- Veterans Affairs Medical Center - Milwaukee (Zablocki) - Milwaukee
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- CCOP - MainLine Health - Wynnewood
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Illinois
- CCOP - Carle Cancer Center - Urbana
New Jersey
- Veterans Affairs Medical Center - East Orange - East Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 1998-09-01 |
| Est. Completion | 2009-05-01 |
| Phase | Phase 2 |
What the finished NCT00003129 record still lists
NCT00003129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which valrubicin is the first listed.
NCT00003129 lists 10 locations in 5 states (Wisconsin, Pennsylvania, Florida).
Frequently Asked Questions
What is clinical trial NCT00003129 about?
NCT00003129 is a clinical study titled "Chemotherapy in Treating Patients With Early-Stage Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating patients with early-stage bladder cancer that has not responded to BCG therapy.
What is the current status of trial NCT00003129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 1998-09-01. Estimated completion is 2009-05-01.
What conditions does trial NCT00003129 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00003129?
The interventions under investigation include: valrubicin (DRUG).
Who is sponsoring clinical trial NCT00003129?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003129 being conducted?
This trial has 10 study locations across Florida, Illinois, New Jersey, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003129's enrollment target sits among peer trials
75 97th of 175 higher than 79 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI